Cullinan Therapeutics, Inc.2024财年第二财季实现净利润-42.03百万美元，同比减少30.49%

自选股智能写手08-17

8月17日，Cullinan Therapeutics, Inc.（CGEM.US）公布财报，公告显示公司2024财年第二财季净利润为-42.03百万美元，同比减少30.49%；其中营业收入为0.00美元，每股基本收益为-0.76美元。从资产负债表来看，Cullinan Therapeutics, Inc.（CGEM.US）总负债25.00百万美元，其中短期债务1.22百万美元，资产负债比为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460249429?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-17 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2460249429","market":"us","top_or_hot":-1,"title":"Cullinan Therapeutics, Inc.2024财年第二财季实现净利润-42.03百万美元，同比减少30.49%","media":"自选股智能写手","content":"<div>\n<p>8月17日，Cullinan Therapeutics, Inc.（CGEM.US）公布财报，公告显示公司2024财年第二财季净利润为-42.03百万美元，同比减少30.49%；其中营业收入为0.00美元，每股基本收益为-0.76美元。从资产负债表来看，Cullinan Therapeutics, Inc.（CGEM.US）总负债25.00百万美元，其中短期债务1.22百万美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000618959f2d73&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cullinan Therapeutics, Inc.2024财年第二财季实现净利润-42.03百万美元，同比减少30.49%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCullinan Therapeutics, Inc.2024财年第二财季实现净利润-42.03百万美元，同比减少30.49%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-17 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000618959f2d73&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月17日，Cullinan Therapeutics, Inc.（CGEM.US）公布财报，公告显示公司2024财年第二财季净利润为-42.03百万美元，同比减少30.49%；其中营业收入为0.00美元，每股基本收益为-0.76美元。从资产负债表来看，Cullinan Therapeutics, Inc.（CGEM.US）总负债25.00百万美元，其中短期债务1.22百万美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000618959f2d73&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000618959f2d73&s=b","article_id":"2460249429","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000618959f2d73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460249429","pubTimestamp":1723824039,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月17日，Cullinan Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-42.03百万美元，同比减少30.49%；其中营业收入为0.00美元，每股基本收益为-0.76美元。从资产负债表来看，Cullinan Therapeutics, Inc.总负债25.00百万美元，其中短期债务1.22百万美元，资产负债比为0.28，流动比率为0.29。机构评级：截至2024年8月17日，当前有7家机构对Cullinan Therapeutics, Inc.目标价做出预测，其中目标均价为32.71美元，其中最低目标价为28.00美元，最高目标价为40.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","CGEM":"Cullinan Therapeutics"},"translate_title":"Cullinan Therapeutics, Inc. achieved net profit of-42.03 million in the second fiscal quarter of fiscal 2024, a year-on-year decrease of 30.49%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGEM":1,"LENZ":1},"content_text":"8月17日，Cullinan Therapeutics, Inc.（CGEM.US）公布财报，公告显示公司2024财年第二财季净利润为-42.03百万美元，同比减少30.49%；其中营业收入为0.00美元，每股基本收益为-0.76美元。从资产负债表来看，Cullinan Therapeutics, Inc.（CGEM.US）总负债25.00百万美元，其中短期债务1.22百万美元，资产负债比为0.28，流动比率为0.29。机构评级：截至2024年8月17日，当前有7家机构对Cullinan Therapeutics, Inc.目标价做出预测，其中目标均价为32.71美元，其中最低目标价为28.00美元，最高目标价为40.00美元。公司简介：Cullinan Therapeutics Inc是一家生物制药公司。它拥有多样化的临床阶段资产组合，可抑制疾病的关键驱动因素或利用免疫系统消除肿瘤和自身免疫性疾病中的病变细胞。 它对肿瘤学、免疫学和转化医学的理解，创造了差异化的想法，确定了适当的目标，并选择最佳的方式来开发针对各种癌症和自身免疫适应症的变革性疗法。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460249429"}